Spots Global Cancer Trial Database for 68Ga DOTATATE PET/CT in Neuroendocrine Tumors (Expanded Access)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: 68Ga DOTATATE PET/CT in Neuroendocrine Tumors (Expanded Access)
Official Title: 68Ga-DOTATATE Imaging in Neuroendocrine Tumors
Study ID: NCT02174679
Interventions
Study Description
Brief Summary: To evaluate 68Ga-DOTATATE PET/CT for staging of patients with carcinoid, neuroendocrine tumors, medullary thyroid cancer and other cancers expressing somatostatin receptors.
Detailed Description: This is an expanded access study with a total of 300 participants with NET and suspected SSTR positive tumors. Eligible participants will undergo baseline assessments at enrollment. Study participants will receive 68Ga-DOTATATE and will undergo a PET/CT imaging study. All patients referred by Oncologists will be screened by a UCLA Nuclear Medicine physician and then accepted for scanning if clinically appropriate.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
UCLA Hospital, Los Angeles, California, United States
Contact Details
Name: Johannes Czernin, MD
Affiliation: University of California, Los Angeles
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
